An effort by President Trump's administration to curb advertising for pharmaceutical drugs on television is posing creating a potential marketing hurdle for some of the country's largest drugmakers while threatening a key revenue stream for media companies.

Advertising and pharmaceutical industry experts say an executive order Trump signed this week could pose an existential threat to the business model of both drugmakers and the media companies which raked in an estimated $5 billion in advertising revenue from pharmaceutical companies in 2024.

The order instructs the Department of Health and Human Services to ensure “transparency and accuracy” in direct-to-consumer advertising, including requiring greater disclosures of side effects in television and other ads.

The order stops short of

See Full Page